HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Molecular dissection of HBV evasion from restriction factor tetherin: A new perspective for antiviral cell therapy.

Abstract
Viruses have evolved various strategies to escape from the innate cellular mechanisms inhibiting viral replication and spread. Extensive evidence has highlighted the ineffectiveness of interferon (IFN) therapy against chronic hepatitis B virus (HBV) infection, implying the existence of mechanisms by which HBV evades IFN-induced antiviral responses. In our current study, we demonstrate that HBV surface protein (HBs) plays a crucial role in counteracting the IFN-induced antiviral response mediated by tetherin (also known as BST-2). The type I IFN treatment of HBV-producing cells marginally but significantly inhibited the release of HBsAg and viral DNA, but this release was recovered by the knockdown of tetherin. HBs can interact with tetherin via its fourth transmembrane domain thereby inhibiting its dimerization and antiviral activity. The expression of a tetherin mutant devoid of the HBs-binding domain promoted a prominent restriction of HBV particle production that eventually resulted in the alleviation of caspase-1-mediated cytotoxicity and interleukin-1β secretion in induced pluripotent stem cell (iPSC)-derived hepatocytes. Our current results thus reveal a previously undescribed molecular link between HBV and tetherin during the course of an IFN-induced antiviral response. In addition, strategies to augment the antiviral activity of tetherin by impeding tetherin-HBs interactions may be viable as a therapeutic intervention against HBV.
AuthorsKei Miyakawa, Satoko Matsunaga, Koichi Watashi, Masaya Sugiyama, Hirokazu Kimura, Naoki Yamamoto, Masashi Mizokami, Takaji Wakita, Akihide Ryo
JournalOncotarget (Oncotarget) Vol. 6 Issue 26 Pg. 21840-52 (Sep 08 2015) ISSN: 1949-2553 [Electronic] United States
PMID26334101 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD
  • Antiviral Agents
  • BST2 protein, human
  • GPI-Linked Proteins
  • Hepatitis B Surface Antigens
  • Interferon Type I
Topics
  • Antigens, CD (immunology)
  • Antiviral Agents (pharmacology)
  • GPI-Linked Proteins (immunology)
  • HEK293 Cells
  • Hep G2 Cells
  • Hepatitis B Surface Antigens (immunology)
  • Hepatitis B virus (immunology)
  • Hepatitis B, Chronic (drug therapy, immunology, virology)
  • Hepatocytes (drug effects, immunology, virology)
  • Humans
  • Interferon Type I (immunology, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: